HC Wainwright & Co. Reiterates Buy on X4 Pharmaceuticals, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on X4 Pharmaceuticals (NASDAQ:XFOR) and maintained a price target of $5.
June 28, 2024 | 11:39 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on X4 Pharmaceuticals and maintained a price target of $5, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $5 price target by HC Wainwright & Co. suggests strong confidence in X4 Pharmaceuticals' future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100